FAST Company


Matrubials, Inc. is developing novel mammalian milk-protein derived peptides for treatment of severe bacterial infections. Our portfolio includes antibacterial peptides from a natural food source for the newborn, milk, which offers a safety dossier defined by lactation. In comparison to currently available antibiotics and newer candidates being developed by our competitors, our therapeutics are rapidly acting and selective, thus preventing severe alteration in homeostasis via retention of the beneficial microbiota. Our next inflection point is evaluation of the molecules in pre-clinical host impact and early safety studies, which will aid clinical development and preparation of the portfolio towards regulatory applications for topical treatments, with an initial focus on women’s health.